Literature DB >> 29376005

Amniotic membrane transplantation with topical interferon alfa-2b after excision of ocular surface squamous neoplasia.

Hua-Tao Xie1, Ying-Ying Zhang1, Dong-Ling Jiang1, Jun Wu1, Jia-Song Wang1, Ming-Chang Zhang1.   

Abstract

To evaluate the outcome of amniotic membrane transplantation (AMT) after tumor excision followed by topical interferon alfa-2b (IFNα2b) drops for primary ocular surface squamous neoplasia (OSSN). Twelve eyes of 12 patients with a mean age of 66±10y were included. The average follow-up was 23±10mo. All 12 patients had limbal involvement. Smooth ocular surface and transparent cornea were achieved in all cases. No sign of inflammation, neovascularization, symblepharon or recurrence was noted at the last follow-up. We conclude that AMT with topical IFNα2b drops restores a healthy ocular surface in OSSN without recurrence.

Entities:  

Keywords:  amniotic membrane; carcinoma; dysplasia; interferon; ocular surface squamous neoplasia

Year:  2018        PMID: 29376005      PMCID: PMC5767672          DOI: 10.18240/ijo.2018.01.24

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  15 in total

1.  How does amniotic membrane work?

Authors:  Scheffer C G Tseng; Edgar M Espana; Tetsuya Kawakita; Mario A Di Pascuale; Wei Li; Hua He; Tzong-Shyne Liu; Tae-Hee Cho; Ying-Ying Gao; Lung-Kun Yeh; Chia-Yang Liu
Journal:  Ocul Surf       Date:  2004-07       Impact factor: 5.033

Review 2.  Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture.

Authors:  J A Shields; C L Shields; P De Potter
Journal:  Arch Ophthalmol       Date:  1997-06

3.  Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.

Authors:  Anat Galor; Carol L Karp; Patrick Oellers; Andrew A Kao; Amany Abdelaziz; William Feuer; Sander R Dubovy
Journal:  Ophthalmology       Date:  2012-06-14       Impact factor: 12.079

Review 4.  Ocular surface squamous neoplasia.

Authors:  G A Lee; L W Hirst
Journal:  Surv Ophthalmol       Date:  1995 May-Jun       Impact factor: 6.048

5.  Amniotic membrane transplantation in surgical management of ocular surface squamous neoplasias: long-term results.

Authors:  M Palamar; E Kaya; S Egrilmez; T Akalin; A Yagci
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

6.  Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors.

Authors:  Carol L Shields; Hakan Demirci; Ekaterina Karatza; Jerry A Shields
Journal:  Ophthalmology       Date:  2004-09       Impact factor: 12.079

7.  Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.

Authors:  A Galor; C L Karp; S Chhabra; S Barnes; E C Alfonso
Journal:  Br J Ophthalmol       Date:  2009-06-02       Impact factor: 4.638

8.  Ocular surface squamous neoplasia after corneal graft.

Authors:  Aparna Ramasubramanian; Carol L Shields; Neelema Sinha; Jerry A Shields
Journal:  Am J Ophthalmol       Date:  2009-10-20       Impact factor: 5.258

9.  Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia.

Authors:  Madhura G Joag; Adam Sise; Juan Carlos Murillo; Ibrahim Osama Sayed-Ahmed; James R Wong; Carolina Mercado; Anat Galor; Carol L Karp
Journal:  Ophthalmology       Date:  2016-03-27       Impact factor: 12.079

Review 10.  HC-HA/PTX3 Purified From Amniotic Membrane as Novel Regenerative Matrix: Insight Into Relationship Between Inflammation and Regeneration.

Authors:  Scheffer C G Tseng
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04-01       Impact factor: 4.799

View more
  2 in total

1.  Topical Chemotherapy for Treating Ocular Surface Squamous Neoplasia with a Combination of Interferon α-2b and 5-Fluorouracil.

Authors:  Wen Geng; Jia-Song Wang; Bing-Jie Shi; Hua-Tao Xie; Ming-Chang Zhang
Journal:  Ophthalmol Ther       Date:  2022-06-15

Review 2.  Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence.

Authors:  Maria Vittoria Cicinelli; Alessandro Marchese; Francesco Bandello; Giulio Modorati
Journal:  Ophthalmol Ther       Date:  2018-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.